Cryo-Cell International, Inc.

Equities

CCEL

US2288951088

Healthcare Facilities & Services

Delayed Nyse Other stock markets 12:45:45 2024-05-02 pm EDT			5-day change	1st Jan Change
8.35 ^USD	+0.72%		+7.05%	+45.22%

Apr. 15	Cryo-Cell International, Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	CI
Mar. 25	Cryo-Cell International to Spin Off Celle Unit, Explore Strategic Alternatives; Shares Jump	MT

Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011.

April 21, 2023 at 04:33 pm EDT

From December 1, 2022 to February 28, 2023, the company has repurchased 57,281 shares, representing 0.67% for $0.2 million. With this, the company has completed the repurchase of 4,211,287 shares, representing 42.96% for $12.98 million under the buyback announced on December 12, 2011.

Latest news about Cryo-Cell International, Inc.

Cryo-Cell International, Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	Apr. 15	CI
Cryo-Cell International to Spin Off Celle Unit, Explore Strategic Alternatives; Shares Jump	Mar. 25	MT
Cryo-Cell to Explore Strategic Alternatives, Spin-Off Celle	Mar. 24	CI
Cryo-Cell International, Inc. agreed to Spin-Off Celle Corp.	Mar. 24	CI
Cryo-Cell International, Inc. Reports Earnings Results for the Full Year Ended November 30, 2023	Feb. 28	CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011.	23-10-12	CI
Cryo-Cell International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2023	23-10-12	CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011.	23-07-14	CI
Cryo-Cell International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2023	23-07-14	CI
Cryo-Cell International, Inc.(NYSEAM:CCEL) added to Russell 3000E Value Index	23-06-23	CI
Cryo-Cell International, Inc.(NYSEAM:CCEL) added to Russell Microcap Value Index	23-06-23	CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011.	23-04-21	CI
Cryo-Cell International, Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023	23-04-21	CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011.	23-02-28	CI
Cryo-Cell International, Inc. Reports Earnings Results for the Full Year Ended November 30, 2022	23-02-28	CI
Insider Buy: Cryo Cell International	22-11-10	MT
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011.	22-10-18	CI
Cryo-Cell International, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022	22-10-18	CI
Cryo-Cell International, Inc. Primary Exchange Listing will Change to New York Stock Exchange from Nasdaq Capital Market	22-08-30	CI
Maxim Starts Cryo-Cell International at Buy With $12 Price Target	22-08-29	MT
Cryo-Cell International, Inc.(NYSEAM:CCEL) dropped from NASDAQ Composite Index	22-08-29	CI
Cryo-Cell International to Transfer Listing to NYSE American Stock Exchange	22-08-17	MT
Cryo-Cell International, Inc. Enters into A Credit Agreement with Susser Bank	22-07-22	CI
Tranche Update on Cryo-Cell International, Inc.'s Equity Buyback Plan announced on December 12, 2011.	22-07-11	CI
Cryo-Cell International, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022	22-07-11	CI

Chart Cryo-Cell International, Inc.

Duration

Period

More charts

Company Profile

Cryo-Cell International, Inc. is a cord blood banking company. The Company operates through three segments: cellular processing and cryogenic storage for family use, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells; manufacture of PrepaCyte CB Processing System (PrepaCyte CB) units, the processing technology used to process umbilical cord blood stem cells, and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company stores approximately 235,000 cord blood and cord tissue specimens. The specimens are stored in commercially available cryogenic storage units at its technologically and operationally advanced facility. The Company markets its cord blood stem cell preservation services directly to expectant parents and by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals.

Sector

Healthcare Facilities & Services

Calendar

2024-07-11 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Cryo-Cell International, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

8.29 USD

Average target price

9 USD

Spread / Average Target

+8.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
CRYO-CELL INTERNATIONAL, INC.	+45.22%	67.19M
HCA HEALTHCARE, INC.	+13.78%	81.84B
CVS HEALTH CORPORATION	-31.08%	70.69B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+9.37%	29.03B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.12%	16.97B
FRESENIUS SE & CO. KGAA	-0.36%	16.83B
QUEST DIAGNOSTICS INCORPORATED	-1.38%	15.28B
FRESENIUS MEDICAL CARE AG	+5.90%	12.41B
DAVITA INC.	+35.60%	12.26B
EUROFINS SCIENTIFIC SE	-4.20%	11.86B

Other Healthcare Facilities & Services